Browse by Phase
Phase 2 Clinical Trials
Phase 2 trials study whether a drug works in people with a specific disease or condition. These studies enroll 100–300 participants and also continue to evaluate safety.
Total Trials
1,083
Recruiting Now
1,083
Top Conditions in Phase 2
Frequently Asked Questions — Phase 2 Trials
What does a Phase 2 clinical trial evaluate?
Phase 2 trials assess whether a drug or treatment works in people with a specific disease or condition. Enrolling 100–300 participants, these studies collect preliminary efficacy data while continuing to monitor safety and identify the optimal dosing regimen. A successful Phase 2 outcome is required to advance to large-scale Phase 3 testing.
How long do Phase 2 trials typically take?
Phase 2 clinical trials typically run for 1–4 years, depending on the condition, endpoint complexity, and enrollment rate. Rare disease trials or those with long-term outcome measures may run longer. Many sponsors run Phase 2 studies at multiple sites simultaneously to accelerate recruitment.
Who can participate in a Phase 2 clinical trial?
Eligibility for Phase 2 trials is defined by specific inclusion and exclusion criteria. Participants are typically patients diagnosed with the condition under study and may or may not have received prior treatment. Age, disease stage, comorbidities, and laboratory values are common eligibility factors. Review each trial's criteria on ClinicalTrials.gov for specific requirements.
Active Phase 2 Studies
NCT05135975 Phase 2
Recruiting
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurre...
Condition
Neuroblastoma
Enrollment
86 pts
Location
United States
Sponsor
Nationwide Children's Hospital
NCT05733000 Phase 2
Recruiting
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil o...
Condition
Advanced Biliary Tract Carcinoma
Enrollment
94 pts
Location
United States
Sponsor
Northwestern University
NCT06867536 Phase 2
Recruiting
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refrac...
Condition
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment
40 pts
Location
China
Sponsor
Liling Zhang
NCT03290534 Phase 2
Recruiting
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR Civa...
Condition
Lung Cancer
Enrollment
40 pts
Location
United States
Sponsor
CivaTech Oncology
NCT07002034 Phase 2
Recruiting
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medic...
Condition
Adjustment Disorder
Enrollment
100 pts
Location
United States
Sponsor
Reunion Neuroscience Inc
NCT06342167 Phase 2
Recruiting
Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonut...
Condition
Locally Advanced Esophageal Squamous Cell Carcinoma
Enrollment
57 pts
Location
China
Sponsor
Cancer Institute and Hospital,
NCT07110064 Phase 2
Recruiting
QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pan...
Condition
Advance Pancreatic Cancer
Enrollment
80 pts
Location
China
Sponsor
Du Juan
NCT06161532 Phase 2
Recruiting
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitou...
Condition
Small Cell Carcinoma of the Bladder
Enrollment
60 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT07007572 Phase 2
Recruiting
Evaluation Of Marginal Bone Height Changes And Biting Force In Screw Retained Im...
Condition
Biting Forces
Enrollment
14 pts
Location
Egypt
Sponsor
Cairo University
NCT05564377 Phase 2
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally A...
Condition
Advanced Malignant Solid Neoplasm
Enrollment
2,900 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT05726292 Phase 2
Recruiting
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant...
Condition
Prostate Cancer
Enrollment
90 pts
Location
United States
Sponsor
University of Chicago
NCT07523581 Phase 2
Recruiting
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exalur...
Condition
Alport Syndrome, X-Linked
Enrollment
24 pts
Location
United States, United Kingdom
Sponsor
Eloxx Pharmaceuticals, Inc.
NCT06420167 Phase 2
Recruiting
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Condition
Renal AL Amyloidosis
Enrollment
20 pts
Location
United States
Sponsor
Barbara Ann Karmanos Cancer In
NCT05662111 Phase 2
Recruiting
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome
Condition
Fahr Disease
Enrollment
98 pts
Location
Netherlands, United Kingdom
Sponsor
UMC Utrecht
NCT06951464 Phase 2
Recruiting
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-...
Condition
Non-Small Cell Lung Cancer
Enrollment
40 pts
Location
China
Sponsor
Sichuan University
NCT06635681 Phase 2
Recruiting
Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgrou...
Condition
AML (Acute Myelogenous Leukemia)
Enrollment
380 pts
Location
China
Sponsor
Institute of Hematology & Bloo
NCT07390500 Phase 2
Recruiting
Assessment of the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia...
Condition
Myopia
Enrollment
150 pts
Location
Israel
Sponsor
NovaSight
NCT07604909 Phase 2
Recruiting
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Thera...
Condition
Colorectal Cancer
Enrollment
40 pts
Location
China
Sponsor
Fudan University
NCT06410599 Phase 2
Recruiting
Pharmacologic Treatment Augmentation in Chronic Depression
Condition
Major Depressive Disorder
Enrollment
60 pts
Location
Germany
Sponsor
University Hospital Tuebingen
NCT04804241 Phase 2
Recruiting
Senicapoc in Alzheimer's Disease
Condition
Mild Cognitive Impairment
Enrollment
55 pts
Location
United States
Sponsor
University of California, Davi
NCT05182957 Phase 2
Recruiting
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refrac...
Condition
Relapsed/Refractory Peripheral T-cell Lymphoma
Enrollment
31 pts
Location
China
Sponsor
The First Affiliated Hospital
NCT05010031 Phase 2
Recruiting
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Geneti...
Condition
Metastatic Cancer
Enrollment
45 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
NCT06345495 Phase 2
Recruiting
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis ...
Condition
Splenomegaly
Enrollment
30 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06429839 Phase 2
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Condition
Esophageal Cancer
Enrollment
55 pts
Location
China
Sponsor
Cancer Institute and Hospital,
NCT07548177 Phase 2
Recruiting
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride...
Condition
Alveolar Soft Part Sarcoma
Enrollment
33 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology